Oscotec Inc.
KOE: 039200.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Sung-Hee Son
- Employees
- 50
- Headquarters
- Seongnam-si, South Korea
- IPO year
- 2007
- Market cap
- ₩2T
- Website
- https://www.oscotec.com
Loading 039200…
Loading profile data…Frequently asked questions about 039200
What does Oscotec Inc. (039200.KQ) do?
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-...
Where does 039200.KQ trade?
Oscotec Inc. (039200.KQ) trades on the KOSDAQ.
What sector is 039200.KQ in?
Oscotec Inc. (039200.KQ) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Oscotec Inc.?
Sung-Hee Son is the chief executive officer of Oscotec Inc. (039200.KQ).
Where is Oscotec Inc. headquartered?
Oscotec Inc. is headquartered in South Korea.
Does 039200.KQ pay a dividend?
Oscotec Inc. (039200.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 039200.KQ go public?
Oscotec Inc. (039200.KQ) completed its initial public offering in 2007.